Table 3.

Cost-Effectiveness of Real-Time Continuous Glucose Monitoring in Patients With Type 1 Diabetes.

Source	Setting/population	Cost per QALY gained
Huang et al67	T1DM, Juvenile Diabetes Research Foundation-CGM trials, CGM vs SMBG, 2 cohorts: (1) A1c < 7%, all ages; and (2) A1c ≥ 7.0% and ≥ 25 years of age	When considering immediate quality of life benefit:
		$98 679 for A1c ≥ 7.0% cohort and $78 943 for A1c < 7% cohort.
McQueen et al68	T1DM, intensive insulin therapy with CGM (+SMBG) vs intensive insulin therapy with SMBG only, US	Using their individualized model: $45 033
Ly et al68	T1DM, sensor-augmented pump with low glucose suspend in hypoglycemic unaware patients	Over 6 months, cost per QALY gained is Australian $40 908